Next Article in Journal
In Vitro, Ex Vivo and In Vivo Techniques to Study Neuronal Migration in the Developing Cerebral Cortex
Next Article in Special Issue
Toward a Multifactorial Conception of the Gilles de la Tourette Syndrome and Persistent Chronic Tic Disorder
Previous Article in Journal
Neurobehavioral Outcomes of Mild Traumatic Brain Injury: A Mini Review
Open AccessCase Report

Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols

1
Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany
2
Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstraße 1a, Leipzig 04103, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
Academic Editors: Kieron O’Connor and Marc Lavoie
Brain Sci. 2017, 7(5), 47; https://doi.org/10.3390/brainsci7050047
Received: 7 March 2017 / Revised: 5 April 2017 / Accepted: 19 April 2017 / Published: 26 April 2017
(This article belongs to the Special Issue Cerebral Etiology and Treatment of the Gilles de la Tourette Syndrome)
Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully treated with nabiximols. Our patient was a 22-year-old male suffering from severe and complex TS. Treatment with nabiximols was commenced at a dose of 1 puff/day (= 100 μL containing 2.7 mg THC and 2.5 mg cannabidiol (CBD)) and slowly increased up to a dosage of 3 × 3 puffs/day (= 24.3 mg THC and 22.5 mg CBD). Several clinical measures for tics, premonitory urges, and global impairment were acquired before and after two weeks of treatment. Treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects. Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS. Given the positive response exhibited by the patient highlighted in this report, further investigation of the effects of nabiximols is proposed on a larger group of patients in a clinical trial setting. View Full-Text
Keywords: Tourette syndrome; tic disorders; nabiximols; endocannabinoid system Tourette syndrome; tic disorders; nabiximols; endocannabinoid system
Show Figures

Figure 1

MDPI and ACS Style

Kanaan, A.S.; Jakubovski, E.; Müller-Vahl, K. Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. Brain Sci. 2017, 7, 47.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop